Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, LENZ Therapeutics Inc (NASDAQ: LENZ) closed at $38.77 up 2.43% from its previous closing price of $37.85. In other words, the price has increased by $2.43 from its previous closing price. On the day, 0.72 million shares were traded. LENZ stock price reached its highest trading level at $39.24 during the session, while it also had its lowest trading level at $37.87.
Ratios:
For a deeper understanding of LENZ Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 20.54 and its Current Ratio is at 20.54. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On March 18, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $60.
On September 27, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $37.Raymond James initiated its Outperform rating on September 27, 2024, with a $37 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 10 ’25 when Versant Venture Capital VI, L. sold 191,376 shares for $34.00 per share. The transaction valued at 6,506,784 led to the insider holds 1,575,899 shares of the business.
Versant Venture Capital VI, L. sold 200,000 shares of LENZ for $6,093,000 on Jun 27 ’25. The 10% Owner now owns 1,767,275 shares after completing the transaction at $30.46 per share. On Jun 20 ’25, another insider, Versant Venture Capital VI, L., who serves as the 10% Owner of the company, sold 133,924 shares for $30.25 each. As a result, the insider received 4,051,201 and left with 1,967,275 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LENZ now has a Market Capitalization of 1105801856 and an Enterprise Value of 897333632. For the stock, the TTM Price-to-Sale (P/S) ratio is 221.16 while its Price-to-Book (P/B) ratio in mrq is 5.35. Its current Enterprise Value per Revenue stands at 179.467 whereas that against EBITDA is -14.504.
Stock Price History:
The Beta on a monthly basis for LENZ is 0.53, which has changed by 0.72311115 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, LENZ has reached a high of $41.70, while it has fallen to a 52-week low of $16.53. The 50-Day Moving Average of the stock is 20.09%, while the 200-Day Moving Average is calculated to be 34.94%.
Shares Statistics:
For the past three months, LENZ has traded an average of 406.12K shares per day and 957670 over the past ten days. A total of 28.50M shares are outstanding, with a floating share count of 23.59M. Insiders hold about 17.28% of the company’s shares, while institutions hold 92.20% stake in the company. Shares short for LENZ as of 1753920000 were 3822202 with a Short Ratio of 9.41, compared to 1751241600 on 3668552. Therefore, it implies a Short% of Shares Outstanding of 3822202 and a Short% of Float of 24.82.
Earnings Estimates
The market rating for LENZ Therapeutics Inc (LENZ) is a result of the insights provided by 5.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.63 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$2.19 and -$2.75 for the fiscal current year, implying an average EPS of -$2.56. EPS for the following year is -$2.5, with 6.0 analysts recommending between -$1.75 and -$3.65.
Revenue Estimates
Based on 8 analysts’ estimates, the company’s revenue will be $49.74M in the next fiscal year. The high estimate is $60.28M and the low estimate is $41.17M.
